All but two women with minor to severe stress incontinence remain continent 1 year after treatment with their own muscle-derived stem cells, according to the authors of a small Austrian study presented at the Radiological Society of North America annual meeting.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.